Humana (NYSE:HUM) Stock Price Expected to Rise, Evercore Analyst Says

Humana (NYSE:HUM) had its price objective boosted by investment analysts at Evercore from $180.00 to $195.00 in a research note issued on Wednesday,MarketScreener reports. Evercore’s price objective indicates a potential downside of 2.73% from the company’s current price.

A number of other brokerages have also issued reports on HUM. Sanford C. Bernstein restated an “outperform” rating and issued a $344.00 target price on shares of Humana in a research note on Tuesday, January 6th. Raymond James Financial cut their target price on shares of Humana from $340.00 to $230.00 and set an “outperform” rating on the stock in a research note on Friday, February 13th. Zacks Research upgraded shares of Humana from a “strong sell” rating to a “hold” rating in a research note on Thursday, March 5th. Jefferies Financial Group cut their target price on shares of Humana from $310.00 to $235.00 and set a “buy” rating on the stock in a research note on Thursday, February 12th. Finally, Truist Financial reduced their price objective on Humana from $285.00 to $200.00 and set a “hold” rating on the stock in a research note on Tuesday, February 17th. Seven equities research analysts have rated the stock with a Buy rating, sixteen have given a Hold rating and three have given a Sell rating to the stock. According to MarketBeat, Humana presently has an average rating of “Hold” and a consensus target price of $223.78.

Humana Stock Up 1.7%

HUM stock traded up $3.33 during midday trading on Wednesday, hitting $200.48. 102,521 shares of the company’s stock were exchanged, compared to its average volume of 2,034,647. The company has a current ratio of 2.00, a quick ratio of 2.00 and a debt-to-equity ratio of 0.70. Humana has a 12-month low of $163.11 and a 12-month high of $315.35. The firm has a 50 day moving average price of $180.49 and a 200-day moving average price of $233.91. The stock has a market capitalization of $24.07 billion, a price-to-earnings ratio of 20.35, a price-to-earnings-growth ratio of 1.90 and a beta of 0.44.

Humana (NYSE:HUM) last posted its quarterly earnings data on Wednesday, February 11th. The insurance provider reported ($3.96) earnings per share (EPS) for the quarter, topping the consensus estimate of ($4.01) by $0.05. Humana had a return on equity of 11.43% and a net margin of 0.92%.The company had revenue of $32.64 billion for the quarter, compared to the consensus estimate of $32.08 billion. During the same period in the previous year, the business earned ($2.16) EPS. Humana’s revenue for the quarter was up 11.3% compared to the same quarter last year. Humana has set its FY 2026 guidance at 9.000-9.000 EPS. On average, analysts anticipate that Humana will post 16.47 EPS for the current year.

Insider Buying and Selling

In related news, insider Sanjay K. Shetty bought 810 shares of the firm’s stock in a transaction on Monday, February 23rd. The stock was bought at an average cost of $185.21 per share, for a total transaction of $150,020.10. Following the completion of the purchase, the insider directly owned 11,657 shares in the company, valued at approximately $2,158,992.97. The trade was a 7.47% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.20% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Humana

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Revolve Wealth Partners LLC bought a new position in shares of Humana during the fourth quarter worth about $202,000. Woodline Partners LP lifted its holdings in shares of Humana by 460.0% in the first quarter. Woodline Partners LP now owns 10,192 shares of the insurance provider’s stock valued at $2,697,000 after buying an additional 8,372 shares during the period. Sivia Capital Partners LLC lifted its holdings in shares of Humana by 53.7% in the second quarter. Sivia Capital Partners LLC now owns 1,293 shares of the insurance provider’s stock valued at $316,000 after buying an additional 452 shares during the period. Baird Financial Group Inc. lifted its holdings in shares of Humana by 22.7% in the second quarter. Baird Financial Group Inc. now owns 13,508 shares of the insurance provider’s stock valued at $3,303,000 after buying an additional 2,501 shares during the period. Finally, Cresset Asset Management LLC lifted its holdings in shares of Humana by 10.3% in the second quarter. Cresset Asset Management LLC now owns 2,369 shares of the insurance provider’s stock valued at $581,000 after buying an additional 222 shares during the period. 92.38% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Humana

Here are the key news stories impacting Humana this week:

• Positive Sentiment: CMS finalizes a bigger-than-expected Medicare Advantage rate increase (2.48%), lifting insurer revenue outlooks and triggering the rally in Humana shares. This is the primary catalyst for the move higher. CNBC: Trump administration finalizes better-than-feared Medicare Advantage payment rate
• Positive Sentiment: Analyst and market reaction amplified the move: coverage notes and media reports highlighted Humana as a top beneficiary of the CMS decision, helping push momentum across the managed-care group. Yahoo Finance: Humana Is Up After Stronger-Than-Planned 2027 MA Rate Hike
• Positive Sentiment: Humana launched a value-based Pharmacist Quality Rewards program in Ohio with CPESN USA, reinforcing its care-management and value-based strategy that can improve clinical outcomes and lower costs over time. Business Wire: Humana launches pharmacist rewards program
• Positive Sentiment: Unusual options activity: a sharp uptick in call purchases signals speculative bullish positioning by traders ahead of the earnings and following the CMS news, which can amplify intraday upside.
• Neutral Sentiment: Recent short‑term strength has attracted coverage about whether the move can persist; one market note examines whether the rally will last after the initial reaction. Zacks: Humana Moves Higher — Will This Strength Last?
• Negative Sentiment: Analysts expect Humana to report a double-digit earnings decline in the upcoming Q1 release, which introduces downside risk if guidance or trends disappoint. Barchart: What You Need To Know Ahead of Humana’s Earnings Release
• Negative Sentiment: Wolfe Research lowered its price target (from $325 to $250) even while keeping an outperform rating — a sign some sell‑side views are trimming upside expectations versus prior forecasts. MarketScreener: Wolfe adjusts price target

Humana Company Profile

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.